MGX (Metagenomi Therapeutics) Issuance of Debt: $0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MGX Metagenomi Therapeutics Inc MGX
10 GF Score
Price $1.20
GF Value $0.69
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Metagenomi Therapeutics Issuance of Debt?

Metagenomi Therapeutics MGX -4.00% 10 Issuance of Debt is $0.00 Mil as of Jun. 2026. GuruFocus rates MGX with a GF Score™ of 10/100 and a GF Value™ of $0.69 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Metagenomi Therapeutics's Issuance of Debt for the three months ended in Jun. 2026 was $0.00 Mil.

Metagenomi Therapeutics's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00 Mil.

Metagenomi Therapeutics Issuance of Debt Related Terms

Metagenomi Therapeutics Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Metagenomi Therapeutics's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metagenomi Therapeutics Issuance of Debt Chart

Metagenomi Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
29.97 0.00 0.00 0.00 0.00

Metagenomi Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MGX
10GF Score
Metagenomi Therapeutics Inc MGX
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metagenomi Therapeutics Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of $0.00 Mil mean?
Metagenomi Therapeutics (MGX) has a Issuance of Debt of $0.00 Mil as of Jun. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Metagenomi Therapeutics and its competitors.
Is Metagenomi Therapeutics' Issuance of Debt too high?
Metagenomi Therapeutics' current Issuance of Debt is $0.00 Mil. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' Issuance of Debt compare to BYSI and EXOZ?
Metagenomi Therapeutics' Issuance of Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Biotechnology company?
A good Issuance of Debt depends on the Biotechnology industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Metagenomi Therapeutics and its competitors. Metagenomi Therapeutics's current Issuance of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Metagenomi Therapeutics (MGX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.69, compared to a current price of $1.20 — trading 73.9% above its estimated fair value. The current Issuance of Debt is $0.00 Mil. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current Issuance of Debt is $0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Metagenomi Therapeutics (MGX) Overvalued in 2026?

Based on GuruFocus' analysis, Metagenomi Therapeutics stock appears to be overvalued. The current stock price of $1.20 is trading 73.9% above its estimated GF Value™ of $0.69. GuruFocus considers Metagenomi Therapeutics to be Significantly Overvalued.

Key valuation signals for MGX:

  • Issuance of Debt: $0.00 Mil
  • GF Value™: $0.69 vs. price of $1.20 (73.9% above fair value)
  • GF Score™: 10/100 with 5 warning signs

No single metric tells the full story. See the MGX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Metagenomi Therapeutics Business Description

Address 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score

Get the complete analysis for MGX

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.20
Price
$0.69
GF Value